Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Detalles Bibliográficos
Autores principales: Udwadia, Zarir F., Barkate, Hanmant, Patil, Saiprasad, Rangwala, Shabbir, Wu, Wen, Caracta, Cynthia F., Tandon, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: GLENMARK PHARMACEUTICALS LIMITED. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012082/
https://www.ncbi.nlm.nih.gov/pubmed/33601032
http://dx.doi.org/10.1016/j.ijid.2021.02.028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012082/
https://www.ncbi.nlm.nih.gov/pubmed/33601032
http://dx.doi.org/10.1016/j.ijid.2021.02.028

Ejemplares similares